Vanda Pharmaceuticals Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.vandapharma.com

Earnings Score
Moat Score

Market Cap $255.62M
PE -16
Debt -
Cash $100.97M
EV -
FCF -$18.20M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$16.39M
EBIT	-$18.09M
ROE	-3%
ROA	-3%
FCF	-$18.20M
Equity	$541.22M
Growth Stability	11%
PE	-15.6
PEG	0.63
PB	0.47
P/FCF	-14.04
P/S	1.34
Price/Cash	0.39
Net Margins	-10%
Gross Margins	94%
Op. Margins	-9%
Earnings CAGR	-5%
Sales Growth YoY	23%
Sales Growth QoQ	-6%
Sales CAGR	6%
FCF CAGR	4%
Equity CAGR	21%
Earnings Stability	0.02
Earnings Growth YoY	-4K%

Earnings Growth QoQ	18%
Earnings CAGR 5Y	-25%
Sales CAGR 5Y	-5%
FCF CAGR 5Y	-5%
Equity CAGR 5Y	6%
Earnings CAGR 3Y	-15%
Sales CAGR 3Y	-15%
FCF CAGR 3Y	-14%
Equity CAGR 3Y	3%
Market Cap	$255.62M
Revenue	$190.86M
Assets	$645.12M
Cash	$100.97M
Shares Outstanding	58.1M
Earnings Score	6%
Moat Score	8%
Working Capital	343.3M
Current Ratio	4.85
Gross Profit	$178.67M
Shares Growth 3y	2%
Equity Growth QoQ	-0%
Equity Growth YoY	-0%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765.

SEC Filings

Direct access to Vanda Pharmaceuticals Inc. (VNDA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Vanda Pharmaceuticals Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Vanda Pharmaceuticals Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -5%

Stability 2%

loading chart...

Vanda Pharmaceuticals Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Vanda Pharmaceuticals Inc..

Years

Calculation mode

= -$234M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$18M	-$19M	-$20M	-$20M	-$21M	-$22M	-$23M	-$23M	-$24M	-$25M	-$26M	-$261M
DCF		-$17M	-$16M	-$15M	-$14M	-$14M	-$13M	-$12M	-$11M	-$11M	-$10M	-$101M
Value	-$234M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-36%	-12%	-9%	13%	51%	9%	12%	2%	1%	-10%
ROA	-	-9%	-8%	7%	6%	6%	7%	2%	1%	-3%
ROE	-	-14%	-12%	9%	28%	5%	7%	1%	0%	-3%

Bad Net Margins (-9.61%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	56%	61%	11%	12%	11%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (11%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	33%	13%	17%	18%	9%	8%	-5%	-24%	-5%
Earnings YoY growth	-	-55%	-14%	-262%	358%	-80%	42%	-81%	-60%	-25%
Equity YoY growth	-	-1%	0%	110%	49%	10%	11%	4%	3%	6%
FCF YoY growth	-	-196%	-62%	-912%	52%	11%	27%	-51%	-60%	-5%